Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754421 | 0.84 | ALOX15 (0.52) | HRH4HRH3ALOX15EGLN1FAAH | |
| SCHEMBL25812917 | 0.82 | HRH4 (0.48) | HRH4HRH3ALOX15LMNASMN1; SMN2 | |
| SCHEMBL3372970 | 0.82 | CNR2 (0.58) | HRH4HRH3EGLN1SMN1; SMN2TP53 | |
| SCHEMBL23836108 | 0.81 | ALOX15 (0.56) | HRH4HRH3ALOX15EGLN1FAAH | |
| SCHEMBL24450206 | 0.80 | HDAC3 (0.58) | LMNAFAAHSMN1; SMN2 | |
| SCHEMBL27417845 | 0.79 | HRH4 (0.47) | HRH4HRH3ALOX15SMN1; SMN2TP53 | |
| SCHEMBL7705452 | 0.78 | NR4A2 (0.48) | HRH4HRH3SMN1; SMN2 | |
| SCHEMBL523253 | 0.77 | RHEB (0.54) | HRH4HRH3LMNASMN1; SMN2 | |
| SCHEMBL11229272 | 0.77 | MAPT (0.47) | HRH4HRH3LMNAFAAHSMN1; SMN2 | |
| SCHEMBL29086821 | 0.77 | CNR2 (0.53) | HRH4HRH3EGLN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HRH4 4259/4885HRH3 3510/4885ALOX15 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.